This article first appeared on GuruFocus. Novo Nordisk (NVO) said it has entered a partnership with Anthropic to expand the use of artificial intelligence in drug research and software development. The agreement is aimed at helping the Wegovy maker address key research challenges and potentially shorten parts of the medicine development process. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator.NVO GF Value chart As part of the collaboration, Novo Nordisk plans to evaluate Anthropic's Claude Science platform, a tool designed to support scientific research workflows. The company said the initial work will focus on applying AI to selected research and development activities.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.